Trevi Therapeutics will announce its financial results for Q3 2026 and provide a corporate update on November 9, 2026. The company is developing Haduvio, an investigational oral therapy for chronic cough in patients with idiopathic pulmonary fibrosis, non-IPF interstitial lung disease, and refractory chronic cough. Haduvio has shown promising clinical trial results in reducing cough frequency and improving patient outcomes. This update is important as there are currently no FDA-approved treatments for these conditions, which affect hundreds of thousands of patients in the U.S.
Trevi Therapeutics' upcoming Q3 2026 financial results and corporate update provide context for readers. For those following the health sector, 48 of 150 priced US health stocks rose while 100 fell. Notable movers include Illumina, Inc. (ILMN) down 18.39%, American Well Corp (AMWL) down 15.15% with 100% buy order activity on Pluang, and Regeneron Pharmaceuticals Inc (REGN) up 13.27% with 80% sell order activity. Data as of Nov 03, 2026 04:11 WIB.
Zentalis Pharmaceuticals awarded 136,000 non-qualified stock options to four newly hired employees as an inducement to join the company, under Nasdaq Listing Rule 5635(c)(4). The options have an exercise price of $1.85, matching the stock's closing p...
Dianthus Therapeutics, a clinical-stage biotech company, granted stock options to three new non-executive employees as inducements for joining the company. The options cover 26,000 shares at an exercise price of $82.25, vesting over four years. This ...
The Federal Home Loan Bank of Atlanta announced the election of three new member directors and the re-election of one independent director to its board for 2026. Suzanne DeFerie was named Chair and Kathy McKinney Vice Chair for 2027, ensuring experie...
The FDA placed Bright Minds Biosciences' planned Phase 2 epilepsy trial for BMB-101 on partial clinical hold due to toxicity findings in mice and insufficient pharmacokinetic and juvenile-toxicity data. This action caused a sharp decline in the compa...
NEAR governance approved a plan to reduce the maximum annual issuance of the NEAR token from 2.5% to 1.6%. This change aims to slow the rate at which new tokens enter circulation, potentially impacting staking rewards by lowering them. The plan inclu...
